.

BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
Medtronic
US Department of Justice
McKesson
Federal Trade Commission
Chinese Patent Office
Novartis
Healthtrust
Cantor Fitzgerald
Farmers Insurance

Generated: November 22, 2017

DrugPatentWatch Database Preview

MARQIBO KIT Drug Profile

« Back to Dashboard

What is the patent landscape for Marqibo Kit, and what generic Marqibo Kit alternatives are available?

Marqibo Kit is a drug marketed by Talon Therap and is included in one NDA. There are three patents protecting this drug.

This drug has forty-five patent family members in sixteen countries.

The generic ingredient in MARQIBO KIT is vincristine sulfate. There are thirteen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the vincristine sulfate profile page.

Medical Subject Heading (MeSH) Categories for MARQIBO KIT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Talon Therap
MARQIBO KIT
vincristine sulfate
INJECTABLE, LIPOSOMAL;INTRAVENOUS202497-001Aug 9, 2012RXYesYes► Subscribe► Subscribe ► Subscribe
Talon Therap
MARQIBO KIT
vincristine sulfate
INJECTABLE, LIPOSOMAL;INTRAVENOUS202497-001Aug 9, 2012RXYesYes► Subscribe► Subscribe► Subscribe
Talon Therap
MARQIBO KIT
vincristine sulfate
INJECTABLE, LIPOSOMAL;INTRAVENOUS202497-001Aug 9, 2012RXYesYes► Subscribe► Subscribe ► Subscribe
Talon Therap
MARQIBO KIT
vincristine sulfate
INJECTABLE, LIPOSOMAL;INTRAVENOUS202497-001Aug 9, 2012RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: MARQIBO KIT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Talon Therap
MARQIBO KIT
vincristine sulfate
INJECTABLE, LIPOSOMAL;INTRAVENOUS202497-001Aug 9, 2012► Subscribe► Subscribe
Talon Therap
MARQIBO KIT
vincristine sulfate
INJECTABLE, LIPOSOMAL;INTRAVENOUS202497-001Aug 9, 2012► Subscribe► Subscribe
Talon Therap
MARQIBO KIT
vincristine sulfate
INJECTABLE, LIPOSOMAL;INTRAVENOUS202497-001Aug 9, 2012► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: MARQIBO KIT

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,060,828Liposomal camptothecins and uses thereof► Subscribe
7,311,924Compositions and methods for treating cancer► Subscribe
7,452,550Liposomal antineoplastic drugs and uses thereof► Subscribe
7,244,450Compositions and methods for treating lymphoma► Subscribe
7,244,448Liposomal antineoplastic drugs and uses thereof► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: MARQIBO KIT

Country Document Number Estimated Expiration
Canada2366787► Subscribe
Israel153676► Subscribe
Japan2015071631► Subscribe
Brazil0009448► Subscribe
Australia7038501► Subscribe
Australia777572► Subscribe
Austria309787► Subscribe
Germany60042968► Subscribe
Japan2002541088► Subscribe
Germany60115045► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
Farmers Insurance
Novartis
Dow
Teva
Citi
Healthtrust
McKesson
Deloitte
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot